...
首页> 外文期刊>Managerial and decision economics: The international journal of research and progress in management economics >Product Differentiation, Competition and Regulation of New Drugs: The Case of Statins in Four European Countries
【24h】

Product Differentiation, Competition and Regulation of New Drugs: The Case of Statins in Four European Countries

机译:新药的产品差异化,竞争和监管:以四个欧洲国家的他汀类药物为例

获取原文
获取原文并翻译 | 示例

摘要

This paper examines the determinants of competition in the statins market across four European countries over the 1991-2002 period. Using IMS data from the UK, Germany, France and the Netherlands, the paper analyses the potential existence of competition between branded statins prior to patent expiry. Against a conceptual background of Cournot type quantity competition with product differentiation a demand function is estimated using panel data analysis for the first and second entrants on the market. The results indicate substitutability across the initial market entrants and the subsequent entrant only. This is consistent with potential price sensitivity in the branded market for statins, even when the overall size of market is growing. The results are indicative due to empirical issues surrounding endogeniety of the price variable.
机译:本文研究了1991-2002年间四个欧洲国家他汀类药物市场竞争的决定因素。利用英国,德国,法国和荷兰的IMS数据,本文分析了在专利到期之前品牌他汀类药物之间存在竞争的潜在可能性。在古诺型数量竞争和产品差异化的概念背景下,使用面板数据分析来估计市场上第一和第二进入者的需求函数。结果表明仅在最初的市场进入者和随后的进入者之间具有可替代性。这与他汀类药物品牌市场中潜在的价格敏感性一致,即使市场的整体规模正在增长。由于围绕价格变量内生性的经验问题,结果具有指示性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号